JO3619B1 - صياغات مثبطة للمناعة - Google Patents

صياغات مثبطة للمناعة

Info

Publication number
JO3619B1
JO3619B1 JOP/2012/0005A JOP20120005A JO3619B1 JO 3619 B1 JO3619 B1 JO 3619B1 JO P20120005 A JOP20120005 A JO P20120005A JO 3619 B1 JO3619 B1 JO 3619B1
Authority
JO
Jordan
Prior art keywords
api
immunosuppressant
formulations
compound
immunosuppressant formulations
Prior art date
Application number
JOP/2012/0005A
Other languages
English (en)
Inventor
Bouillot Philippe
Reynaud Emeric
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44022942&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JO3619(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of JO3619B1 publication Critical patent/JO3619B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

يتعلق الاختراع الحالي بتركيبات صيدلية في الحالة الصلبة تشتمل على سواغ مقبول صيدليا أو أكثر ، و مكون صيدلي فعال (“API”) و الذي يكون مركب بالصيغة A1 أو A2 أو ملح مقبول دوائيا أو ذوبان أو هيدرات منه حيث فيه لا يعرض API لمركب قاعدي.
JOP/2012/0005A 2011-01-07 2012-01-05 صياغات مثبطة للمناعة JO3619B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP11150431 2011-01-07

Publications (1)

Publication Number Publication Date
JO3619B1 true JO3619B1 (ar) 2020-08-27

Family

ID=44022942

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2012/0005A JO3619B1 (ar) 2011-01-07 2012-01-05 صياغات مثبطة للمناعة

Country Status (35)

Country Link
US (3) US20130273161A1 (ar)
EP (2) EP3590507A1 (ar)
JP (2) JP6111202B2 (ar)
KR (2) KR101951966B1 (ar)
CN (1) CN103458877B (ar)
AR (2) AR084801A1 (ar)
AU (1) AU2012204835B2 (ar)
BR (1) BR112013017302B1 (ar)
CA (1) CA2823616C (ar)
CL (1) CL2013001979A1 (ar)
CO (1) CO6761402A2 (ar)
CY (1) CY1122182T1 (ar)
DK (1) DK2661261T3 (ar)
EA (1) EA026144B9 (ar)
EC (1) ECSP13012812A (ar)
ES (1) ES2751920T3 (ar)
GT (1) GT201300178A (ar)
HR (1) HRP20191842T1 (ar)
HU (1) HUE045612T2 (ar)
IL (1) IL227094B (ar)
JO (1) JO3619B1 (ar)
LT (1) LT2661261T (ar)
MA (1) MA34897B1 (ar)
MX (2) MX357304B (ar)
MY (1) MY161162A (ar)
PE (1) PE20140216A1 (ar)
PL (1) PL2661261T3 (ar)
PT (1) PT2661261T (ar)
SG (1) SG191286A1 (ar)
SI (1) SI2661261T1 (ar)
TN (1) TN2013000257A1 (ar)
TW (2) TWI583380B (ar)
UA (1) UA114283C2 (ar)
WO (1) WO2012093161A1 (ar)
ZA (1) ZA201304465B (ar)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6674903B2 (ja) * 2014-04-10 2020-04-01 ノバルティス アーゲー Ｓ１ｐ調節剤即時放出投与レジメン
AU2015246038C1 (en) * 2014-04-10 2018-05-31 Novartis Ag Immunosuppressant formulation
US20180042895A1 (en) 2015-02-26 2018-02-15 Novartis Ag Treatment of autoimmune disease in a patient receiving additionally a beta-blocker
JP6132294B1 (ja) 2015-07-03 2017-05-24 アステラス製薬株式会社 安定な経口投与用医薬組成物
US11629124B2 (en) 2017-03-09 2023-04-18 Novartis Ag Solid forms comprising an oxime ether compound, compositions and methods of use thereof
MX2020007270A (es) 2017-09-27 2020-08-17 Novartis Ag Formulacion parenteral que comprende siponimod.
WO2019064212A1 (en) 2017-09-29 2019-04-04 Novartis Ag DOSAGE DIAGRAM OF SIPONIMOD
CA3074416A1 (en) 2017-09-29 2019-04-04 Novartis Ag Dosing regimen of siponimod
CN109908095A (zh) * 2019-04-08 2019-06-21 肇庆学院 一种西尼莫德片剂及制备方法
WO2021214717A1 (en) 2020-04-23 2021-10-28 Novartis Ag Dosing regimen for the use of siponimod for the treatment of acute respiratory distress syndrome
WO2023172508A1 (en) * 2022-03-09 2023-09-14 Isp Investments Llc Co-processed excipient composition
WO2024126409A1 (en) 2022-12-12 2024-06-20 Synthon B.V. Pharmaceutical composition of siponimod

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3672314B2 (ja) 1994-07-12 2005-07-20 バーウィンド・ファーマスーティカル・サーヴィスィーズ・インコーポレーテッド 防湿性フィルム被覆材組成物、方法および被覆成形物
CN100384398C (zh) * 2002-11-07 2008-04-30 日本泽托克株式会社 口腔用组合物用基质及口腔用组合物
MY150088A (en) 2003-05-19 2013-11-29 Irm Llc Immunosuppressant compounds and compositions
GT200600350A (es) 2005-08-09 2007-03-28 Formulaciones líquidas
KR101600098B1 (ko) 2007-10-12 2016-03-04 노파르티스 아게 스핑고신 1 포스페이트 (ｓ1ｐ) 수용체 조절제를 포함하는 조성물
CN102186473B (zh) 2008-08-18 2014-07-02 诺华股份有限公司 用于治疗周围神经病的化合物
EP2379499B1 (en) * 2008-12-18 2014-04-09 Novartis AG Hydrochloride salt of 1-(4-(1-((E)-4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-ethyl)-2-ethyl-benzyl)-azetidine-3-carboxylic acid
KR20110112352A (ko) 2008-12-18 2011-10-12 노파르티스 아게 1-（4-｛ｌ-［（ｅ）-4-시클로헥실-3-트리플루오로메틸-벤질옥시이미노］-에틸｝-2-에틸-벤질）-아제티딘-3-카르복실산의 신규한 다형체 형태
US20120115840A1 (en) 2008-12-18 2012-05-10 Lech Ciszewski Hemifumarate salt of 1-[4-[1-(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-ethyl]-2-ethyl-benzyl]-azetidine-3-carboxylic acid
SI2379069T1 (sl) 2008-12-22 2015-07-31 Novartis Ag Režim odmerjanja agonista receptorja S1P

Also Published As

Publication number Publication date
UA114283C2 (uk) 2017-05-25
KR102166885B1 (ko) 2020-10-19
KR20140037815A (ko) 2014-03-27
EA026144B9 (ru) 2021-10-26
ZA201304465B (en) 2014-02-26
HUE045612T2 (hu) 2020-01-28
JP2014501770A (ja) 2014-01-23
SG191286A1 (en) 2013-07-31
MY161162A (en) 2017-04-14
CA2823616C (en) 2019-01-29
BR112013017302B1 (pt) 2021-12-07
SI2661261T1 (sl) 2019-11-29
AU2012204835B2 (en) 2015-07-09
TWI610672B (zh) 2018-01-11
US20220064110A1 (en) 2022-03-03
AR124662A2 (es) 2023-04-19
KR101951966B1 (ko) 2019-02-25
CL2013001979A1 (es) 2013-11-22
US20200199069A1 (en) 2020-06-25
PL2661261T3 (pl) 2020-01-31
CN103458877A (zh) 2013-12-18
EA201391018A1 (ru) 2013-11-29
TW201249438A (en) 2012-12-16
TW201609092A (zh) 2016-03-16
JP6111202B2 (ja) 2017-04-05
MX357304B (es) 2018-07-04
EP3590507A1 (en) 2020-01-08
MX2013007909A (es) 2013-08-29
CN103458877B (zh) 2016-06-08
KR20190025727A (ko) 2019-03-11
PE20140216A1 (es) 2014-03-01
ES2751920T3 (es) 2020-04-02
US20130273161A1 (en) 2013-10-17
EP2661261B1 (en) 2019-07-31
JP2017141248A (ja) 2017-08-17
MX371290B (es) 2020-01-24
IL227094B (en) 2019-03-31
NZ612420A (en) 2015-05-29
BR112013017302A2 (pt) 2016-10-25
DK2661261T3 (da) 2019-10-21
WO2012093161A1 (en) 2012-07-12
AR084801A1 (es) 2013-06-26
TN2013000257A1 (en) 2014-11-10
EP2661261A1 (en) 2013-11-13
GT201300178A (es) 2014-12-30
AU2012204835A1 (en) 2013-08-01
CO6761402A2 (es) 2013-09-30
LT2661261T (lt) 2019-10-25
JP6324569B2 (ja) 2018-05-16
HRP20191842T1 (hr) 2019-12-27
TWI583380B (zh) 2017-05-21
ECSP13012812A (es) 2013-09-30
CA2823616A1 (en) 2012-07-12
PT2661261T (pt) 2019-10-25
EA026144B1 (ru) 2017-03-31
CY1122182T1 (el) 2020-11-25
MA34897B1 (fr) 2014-02-01

Similar Documents

Publication Publication Date Title
JO3619B1 (ar) صياغات مثبطة للمناعة
PH12018501807A1 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of diseas
AU2012259422A8 (en) Solid forms of a pharmaceutically active substance
MX2015016344A (es) Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades.
MX2020007023A (es) Analogos detiadiazol y metodos para el tratamiento de afecciones relacionadas con la deficiencia del gen de supervivencia de las neuronas motoras (smn).
MY183312A (en) Pharmaceutical formulation
MY187718A (en) Pharmaceutical formulations
MX2017012295A (es) Derivados formilados n-heterociclicos como inhibidores de fgfr4.
PH12016502246A1 (en) Carboxamide derivatives
MX2016014946A (es) Derivados de carboxamida.
PH12015501386A1 (en) Tricyclic compounds
MX2013011926A (es) Derivados de glicosido y usos de los mismos.
WO2014016754A3 (en) Pharmaceutical compositions of proton pump inhibitor
TN2014000060A1 (en) Benzothiazolone compound
MX2016006667A (es) Derivados de pirrolo-pirrolona y su uso como inhibidores.
JOP20200127A1 (ar) مشتقات بيريدينون واستخدامها كمثبطات alk-2 انتقائية
TN2012000568A1 (en) Sustained-release therapeutic agent for hypertension and renal dysfunction
AU2012225365A8 (en) Peptide deformylase inhibitors
PH12016502247A1 (en) Carboxamide derivatives